PhD Scientific Days 2025
Budapest, 7-9 July 2025
Theoretical and Translational Medicine I.
Investigating the effectiveness of incretin-based therapies in obesity-related obstructive sleep apnea
Előadó neve
Dr. Bardóczi Anna
Előadó munkahelye
Department of Pulmonolgy, University of Semmelweis
Szerző(k) neve és munkahelye
Anna Bardóczi1,2, Zsombor Matics1,2, Caner Turan2,3, Bence Szabó2, Zsolt Molnár2,3,4, Péter Hegyi2,5,6, Veronika Müller1,2, Gábor Horváth1,2
1: Department of Pulmonolgy, University Semmelweis
2: Centre for Translational Medicine, Semmelweis University
3: Department of Anesthesiology and Intensive Therapy, Semmelweis University
4: Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences
5: Institute of Pancreatic Diseases, Semmelweis University
6: Institute for Translational Medicine, Medical School, University of Pécs
Összefoglaló szövege
Introduction: Obstructive sleep apnea (OSA) significantly reduces quality of life and increases mortality, predominantly due to obesity. Conventional treatments, such as positive airway pressure (PAP), often have limited adherence. Incretin-based therapies, notably glucagon-like peptide-1 (GLP-1) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, offer promising obesity management options and thus represent potential treatments for OSA.
Aims: This systematic review and meta-analysis aimed to evaluate the efficacy of incretin-based therapies in reducing apnea-hypopnea index (AHI) and body weight in patients with obesity-related OSA.
Method: We conducted a systematic literature search in Medline, Embase, and Cochrane databases following PRISMA and Cochrane Handbook guidelines. Randomized controlled trials (RCTs) involving incretin-based therapies (liraglutide, tirzepatide) in adult patients with OSA were included. A meta-analysis using random-effects models assessed changes in AHI and body weight.
Results: Five articles reporting six RCTs with 1,024 patients met inclusion criteria. Incretin-based therapies significantly reduced AHI (mean change: -14.45 events/h; 95% CI: -25.90 to -2.99, p<0.001), demonstrating greater improvement compared to standard care (mean difference: -11.61 events/h; 95% CI: -22.91 to -0.31, p=0.046). Body weight decreased significantly with incretin therapies compared to standard care (mean difference: -11.4 kg; 95% CI: -21.93 to -0.88, p=0.041).
Conclusion: Incretin-based therapies effectively reduce body weight and significantly improve OSA severity, measured by AHI. These therapies hold potential as adjunctive or alternative treatments in obesity-related OSA management.
Funding: Funded by the Ph.D. program of the Centre of Translational Medicine, Semmelweis University. No external funders participated in study design or manuscript preparation.